Clinical Trial Update: Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update of Yttrium-90 glass microsphere radioembolization (TheraSphere) for patients with liver metastases, completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cholangiocarcinoma
• Colorectal Neoplasms
• Melanoma
• Neuroendocrine Tumors

Drugs mentioned

• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: Nicholas Fidelman, MD | Conditions: Colorectal Neoplasms, Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2014-12-22